相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
Kevin B. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
R. M. Anforth et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
NRAS mutation status is an independent prognostic factor in metastatic melanoma
John A. Jakob et al.
CANCER (2012)
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET ONCOLOGY (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
Mario E. Lacouture et al.
SUPPORTIVE CARE IN CANCER (2011)
Cetuximab-induced cutaneous toxicity
H. Tomkova et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2010)
IGF-1 induces SREBP-1 expression and lipogenesis in SER-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway
Terry M. Smith et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Improving melanoma classification by integrating genetic and morphologic features
Amaya Viros et al.
PLOS MEDICINE (2008)
Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment
A. R. Tan et al.
ANNALS OF ONCOLOGY (2008)
Number of Nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma
Nancy E. Thomas et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
Distinct clinical and pathological features are associated with the BRAF T1799A(V600E) mutation in primary melanoma
Wendy Liu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
Cutaneous side-effects of kinase inhibitors and blocking antibodies
C Robert et al.
LANCET ONCOLOGY (2005)
分享论文
